65
Participants
Start Date
March 17, 2008
Primary Completion Date
April 15, 2009
Study Completion Date
April 15, 2009
PF-04383119
PF-04383119 200 mcg/kg IV, single dose
Placebo
placebo IV, single dose
The Arthur Smith Institute for Urology, New Hyde Park
University of Rochester Medical Center, Rochester
Triangle Urological Associates, Pittsburgh
Chesapeake Urology Research Associates, Owings Mills
Alliance Urology Specialists, PA, Greensboro
Matrix Research, LLC (Administrative Only), Greer
The Urology Group, Greer
Atlanta Center for Medical Research, Atlanta
Tri-State Urologic Services PSC, Inc. dba The Urology Group, Cincinnati
Metropolitan Urology, Jeffersonville
William Beaumont Hospital, Royal Oak
Michigan Institute of Urology, Troy
Michigan Institute of Urology, Utica
Barnes Jewish West County Hospital, St Louis
Washington University, Division of Urologic Surgery, St Louis
Washington University, St Louis
Quality Clinical Research Inc, Omaha
Regional Urology, LLC, Shreveport
Parkhurst Research Organization, LLC, Bethany
Mobley Research Center, Houston
Boulder Medical Center, Boulder
Pivotal Research Center, Peoria
Citrus Valley Medical Research Inc., Glendora
SD Uro-Research, San Diego
Urology Associates of Central California, Fresno
Integrity Medical Research, LLC, Mountlake Terrace
Northside Internal Medicine, Spokane
Hartford Hospital, Urogynecology Division, Hartford
Hartford Hospital, Hartford
The Connecticut Clinical Research Center, Urology Specialists PC, Middlebury
Waterbury Neurology, Middlebury
Connecticut Urological Research at Grove Hill, New Britain
Coastal Connecticut Research, LLC, New London
Timothy M. Barczak, MD, LLC, New London
Lead Sponsor
Pfizer
INDUSTRY